Legal Challenge Could Put UK Drug Pricing Deal At Risk
The body representing generics and biosimilars companies in the UK is seeking a seat at the table as negotiations on a new voluntary price scheme get under way.
You may also be interested in...
Shortfall In Rebates Could Stymie UK Generics Industry’s Call For Exemptions Under New Pricing Scheme
The UK’s generics and biosimilars industry body, the BGMA, has set out what it wants from the new drug pricing scheme due to start up in January 2024. But a key request – exempting some branded generics and biosimilars from rebates - would leave a hole in the government’s finances.
The publication of two major reports has led the UK government to announce a £650m “Life Sci for Growth” package to bolster the life sciences sector.
UK generics and biosimilars industry association the BGMA is laying the groundwork for new leadership after appointing Sandoz UK head Diane DiGangi Trench as its vice-chair, ahead of her moving up to chair next year.